Artificial Intelligence in Epidemiology Market

Global Artificial Intelligence in Epidemiology Market is valued at USD 287.49 Million in 2021 and expected to reach USD 1815.48 Million by 2028 with a CAGR of 30.1% over the forecast period.

Global Artificial Intelligence in Epidemiology Market: Global Size, Trends, Competitive, And Historical & Forecast Analysis, 2022-2029: The necessity for efficient prevention strategies and the creation of viable therapeutic options has increased with the rising burden of persistent illnesses . Market growth is being fuelled by government-backed initiatives, increased private and venture public investment, and the emergence of AI-focused start-ups globally.

Scope-

The analysis of illnesses' links with potential causes or variables that affect their incidence, geographic distribution, and the evolutionary course is known as epidemiology. Epidemiology is of utmost significance, especially when it comes to public healthcare policy. For instance, it enables the detection or prevention of the emergence of new illnesses or the comeback of established ones.

Artificial intelligence may have a wide range of effects on analytical studies that aim to identify the environmental causes of an illness in this domain. For instance, it may be utilized to determine links between certain actions or sociodemographic traits and the occurrence of illnesses like diabetes, obesity, and cancer. Primarily for applications where traditional statistical approaches are less effective, AI technologies have the ability to understand healthcare and biomedical information.

For large-scale, high-dimensional datasets, the techniques are even more appropriate. As a result, these algorithms may be utilized to resolve issues including streamlining clinical diagnoses, creating prediction models, and discovering correlations between patient characteristics. Large volumes of data may be examined using artificial intelligence. It may be used to characterize the epidemiology of illnesses like cancer using photos or text-based data.

COVID-19 Impact-

The COVID-19 pandemic had a  significant impact  on the world economy. While this influence has created difficulties for several sectors of the worldwide economy, it has also opened up new prospects for others, like  the AI in epidemiology sector. The outbreak has increased the use of AI in the healthcare industry since there is a great demand for digitalization.

The COVID-19 outbreak increased the need for AI technology and made these sophisticated technologies' potential more apparent. Healthcare systems extensively embraced these innovations for the quick identification and diagnosis of various virus strains and made use of tailored data to enhance outbreak management.

Key Players-

The prime players operating in this marketplace are -

• Cerner Corporation (Oracle)
• Cognizant Technology Solutions Corporation
• Intel Corporation
• Epic Systems Corporation
• Komodo Health
• eClinicalWorks LLC
• Artificial Intelligence for Medical Epidemiology (AIME)
• Meditech
• Microsoft Corporation
• Alphabet Inc.
• Siemens Healthineers AG
• Predixion Software
• Bayer Healthcare
• Cardiolyse
• SAS Institute Inc.

Segmentation-

By Deployment:

• Web-based
• On-premise
• Cloud-based

By Application:

• Disease & Syndromic Surveillance
• Infection Prediction & Forecasting
• Monitoring Population Health & Incidence

By End-use:

• Research Labs
• Government & State Agencies
• Healthcare Providers
• Pharmaceutical & Biotechnology Companies

By Regional & Country Level:

• North America

  • U.S.
  • Canada

• Europe

  • U.K.
  • France
  • Germany
  • Italy

• Asia Pacific

  • China
  • Japan
  • India
  • Southeast Asia

• Latin America

  • Brazil
  • Mexico

• Middle East and Africa

  • GCC
  • Africa
  • Rest of Middle East and Africa

Market Drivers-

Increasing Adoption of AI in Drug Development, Rising Healthcare advancement, and Growing Government Investments and contribution are Some of the Major Factors Driving the Market Growth

Growing public understanding on  the importance of innovation in the identification and treatment of persistent diseases will be a key factor in the development of AI technologies in epidemiology. The need for AI technology in epidemiology laboratories will rise as healthcare advancement and research initiatives do as well.

Another growth catalyst for the industry is the widespread application of AI in drug development and research operations. Businesses in the biotech and pharmaceutical industries have also raised their R&D spending. The deployment of AI systems to track the development of syndromic disorders is being driven by this investor interest.

The American National Science Foundation contributed more than USD 7.5 million in August 2022 to support a new study. This study would concentrate on accurately forecasting the development of infectious diseases, the results of mitigating actions, and other national health crisis-related issues.

Increasing Need for Early Illness Diagnosis and Rising Prevalence Of Non-Communicable Diseases (NCDs)

The rise in the need for early illness diagnosis and better understanding is mostly due to the aging world's population, changes in lifestyle along with the  increased incidence of chronic illnesses and infectious diseases.

For example, the WHO estimates that non-communicable diseases (NCDs) would account for 41 million deaths worldwide in 2022 or 74% of all fatalities. 17 million individuals worldwide pass away from an NCD until they turn 70 each year; 86% of these untimely deaths take place in low- and middle-income nations. In order to effectively anticipate illnesses in their early stages based on previous health records, artificial intelligence (AI) technologies are being increasingly used and incorporated into medical infrastructures.

Market Restraints-

Increasing Cost of R&D and Lack of Healthcare Infrastructure Is Expected To Hinder Market Growth

The market's expansion is anticipated to be constrained by apprehension about adopting AI technology. Alongside, high expenses linked with R&D capabilities, medical professionals' resistance to AI-based innovations, clinical risks, and logistical difficulties related to healthcare operations are expected to restrain the market growth.

Additionally, the market is expected to face challenges from a lack of advantageous compensation situations, an absence of innovation infiltration in emerging countries, an absence of compiled patient information, industries related to data sequestering, an absence of interconnectivity, as well as a lack of an appropriate structure.

Geographical Landscape-

North America is Expected to Capture a Major Share in the Global Artificial Intelligence in Epidemiology Market

Geographically, the market for AI  in epidemiology is anticipated to soon have the biggest revenue share. Government authorities have been using AI technologies more often as a result of advancements in medical IT infrastructures, growing healthcare costs, broad technological usage, supportive legislative initiatives, and the existence of multiple significant market rivals.

The effective incorporation of Intelligence in epidemiology will also be facilitated by the involvement of major technology firms. Large biotechnology and pharmaceutical firms may be found in nations like the United States as well as Canada, and they substantially fund research, pointing to a potential outlook for North American AI service providers.

Asia Pacific is Anticipated to grow at the fastest pace over the forecast period

Throughout the projected period, the Asia Pacific region is expected to develop at the quickest rate. The fast advancement of IT technology and business endeavours focusing on AI-based solutions are contributing to the growth.

The acceptance rates are being driven by growing investments made by private entrepreneurs, investment firms, and non-profit groups to improve therapeutic results, data processing, and security, as well as lower costs. One of the main reasons propelling the development of the Asia Pacific market is favorable government policies encouraging and pushing healthcare organizations and healthcare professionals to quickly embrace AI-based technology.

News-

National Institutes of Health (NIH) Launched $130 million investment across four years to hasten the scientific and behavioural research sectors

On September 13^th, 2022; The National Institutes of Health (NIH)  launched a $130 million investment across four years to hasten the scientific and behavioral research sectors' adoption of artificial intelligence (AI). The Bridge to Artificial Intelligence (Bridge2AI) program of the NIH Common Fund had given out four financial resources for projects that generate information and three for the establishment of a Bridge Center for integrating dissemination, and assessment activities.

New biological and behavioral data points will be created as a result of the data generation initiatives, which will also provide technologies and data guidelines for the FAIR principle, which ensures that information is accessible, findable, interoperable, and reusable.

University of Pennsylvania School of Medicine and Children's Hospital of Philadelphia (CHOP) launched the Penn-CHOP Kidney Innovation Center

On August 30^th, 2022; The University of Pennsylvania School of Medicine (Penn Medicine) and Children's Hospital of Philadelphia (CHOP)  established the Penn-CHOP Kidney Innovation Center that will fund studies to enhance patient treatment for both adults and adolescents with kidney damage.

The cooperation will concentrate on preventing kidney illness, detecting it early, and treating it, as well as any complications that may arise since they place a large clinical strain on the whole care continuum. Professionals in medical epidemiology, biostatistics, computational biology, bioinformatics, pathology, genetics, physiology, biochemistry, immunotherapy, pharmacology, genomics, and psychology, as well as other fields, will be gathered at the institute.

The University at Albany plans to launch the University's Ambitious Ambition To Integrate AI-Related Instruction

On November 7^th, 2022; The University at Albany announced its plans to hire a record-breaking 27 new AI-focused faculty employees, launching the university's ambitious ambition to integrate AI-related instruction and development throughout all academic departments. The new employees will work in as many as 20 academic departments at several UAlbany schools and colleges, including those for digital investigations, psychology, welfare programs, arithmetic, and epidemiology.

Report Analysis	Details
Historical data	2016 - 2021
Forecast Period	2022 - 2029
Market Size in 2021:	USD 287.49 Million
Base year considered	2021
Forecast Period CAGR %:	30.1%
Market Size Expected in 2028:	USD 1815.48 Million
Tables, Charts & Figures:	175
Pages	300
Companies	Cerner Corporation (Oracle), Cognizant Technology Solutions Corporation, Intel Corporation, Epic Systems Corporation, Komodo Health, eClinicalWorks LLC, Artificial Intelligence for Medical Epidemiology (AIME), Meditech, Microsoft Corporation, Alphabet Inc., Siemens Healthineers AG, Predixion Software, Bayer Healthcare, Cardiolyse, and SAS Institute, Inc.
Segments Covered	By Deployment, By Application, By End-use
Regional Analysis	North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa